Related Experiment Video
Updated: Aug 25, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
TiSe2-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer
Libin Chen1,2,3, Wang Xue4,5, Jing Cao4,5
1Department of Ultrasound in Medicine, Ningbo First Hospital, Ningbo, 315010, People's Republic of China.
Background:
Pancreatic cancer remains among the most prevalent and aggressive forms of cancer. While immunotherapeutic treatment strategies have shown some promise in affected patients, the benefits of these interventions have been limited by insufficient tumor infiltration by activated T cells.
Results:
Here, Titanium diselenide (TiSe2) nanosheets were synthesized with good stability. When exposed to ultrasound (US), the TiSe2 nanosheets served as a reliable nano-sensitizer capable of inducing large amounts of reactive oxygen species (ROS) mediating sonodynamic therapy (SDT) under hypoxic and normoxic conditions. The tumor-released TAAs induced by TiSe2 nanosheet-mediated SDT promoted immunogenic cell death (ICD) conducive to the maturation of dendritic cells (DCs), and cytokine secretion and the subsequent activation and infiltration of T cells into the tumor. Combining TiSe2-mediated SDT with anti-PD-1 immune checkpoint blockade treatment led to the efficient suppression of the growth of both primary tumor and distant tumor, while simultaneously preventing lung metastasis. These improved immunotherapeutic and anti-metastatic outcomes were associated with activated systematic antitumor immune responses, including the higher levels of DC maturation and cytokine secretion, the increased levels of CD8+ T cells and the decreased levels of Treg cells infiltrated in tumors.
Conclusion:
TiSe2 can be used as a sonosensitizer with good efficacy and high safety to mediate efficient SDT. The combination treatment strategy comprised of TiSe2-mediated SDT and PD-1 blockade activate anti-tumor immune responses effectively thorough inducing ICD, resulting in the inhibition the growth and metastasis of tumor. The combination therapy holds promise as a novel immunotherapy-based intervention strategy for pancreatic cancer patients.
Insights
Titanium diselenide (TiSe2) nanosheets enhance sonodynamic therapy (SDT) for pancreatic cancer. Combining TiSe2-SDT with PD-1 blockade activates anti-tumor immunity, inhibiting tumor growth and metastasis.
Area of Science:
- Biomedical Engineering
- Materials Science
- Oncology
Background:
- Pancreatic cancer is a highly aggressive malignancy with limited treatment options.
- Current immunotherapies for pancreatic cancer show promise but are hindered by poor T cell infiltration into tumors.
Purpose of the Study:
- To investigate the efficacy of Titanium diselenide (TiSe2) nanosheets as a sonosensitizer for sonodynamic therapy (SDT).
- To evaluate the combined therapeutic effect of TiSe2-mediated SDT and anti-PD-1 immune checkpoint blockade on pancreatic tumors and metastasis.
Main Methods:
- Synthesis of stable Titanium diselenide (TiSe2) nanosheets.
- Ultrasound (US) application to induce reactive oxygen species (ROS) generation for SDT.
- Assessment of tumor-released tumor-associated antigens (TAAs), immunogenic cell death (ICD), dendritic cell (DC) maturation, T cell activation, and infiltration.
- Combination therapy of TiSe2-SDT with anti-PD-1 blockade.
Main Results:
- TiSe2 nanosheets effectively mediated SDT by generating ROS under hypoxic and normoxic conditions.
- TiSe2-SDT induced ICD, promoting DC maturation and T cell activation and infiltration.
- The combination of TiSe2-SDT and anti-PD-1 blockade significantly suppressed primary and distant tumor growth and prevented lung metastasis.
- Enhanced systemic antitumor immune responses were observed, including increased CD8+ T cells and decreased regulatory T cells (Treg) in tumors.
Conclusions:
- TiSe2 serves as an effective and safe sonosensitizer for SDT.
- The combination of TiSe2-SDT and PD-1 blockade activates anti-tumor immunity via ICD induction, inhibiting tumor growth and metastasis.
- This combination therapy presents a promising novel immunotherapy strategy for pancreatic cancer.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...

